Review





Similar Products

94
MedChemExpress cxcr4 blocking antibody
nMSC@MT inheriting the original MSCs and could be effectively taken up by BMMSCs. a) Representative confocal images of PMVs with DiI-labeled cell membrane and Tht-labeled cytoplasm. Scale bar = 25 μm (above) and 1 μm (below). b) Illustration showing the co-extrusion procedure of nPMV and melatonin to obtain nMSC@MT. c) Representative TEM image of nMSC@MT. Scale bar = 100 nm. d, e) The sizes and the potential zetas of nPMV and nMSC@MT by DLS (n = 3). f, g) Coomassie brilliant blue and Western blot showing the preservation of stem cell markers, CD146, CD105, CD90, and functional protein, <t>CXCR4,</t> in PMV, nPMV, and nMSC@MT. h) DiI-labeled nMSC@MT (red) was detected in the cytoplasm of BMMSCs, suggesting the endocytosis of nMSC@MT. Scale bar = 10 μm. i) Immunofluorescence showing that a large amount of DiI-labeled nMSC@MT (red), released from the hydrogel, was taken up by CD146-labeled MSCs (green). Scale bar = 50 μm. j) BMMSCs uptake of DiI-labeled nMSC@MT in presence of blocking antibodies (anti-CXCR4) detected via flow cytometry. k) Analysis of the percentage of DiI positive cells in BMMSCs by flow cytometry (n = 3). l, m) Immunofluorescent staining images and corresponding semi-quantitative analysis (n = 3) of the uptake of DiI-labeled nPMV by BMMSCs in presence of blocking antibodies (anti-CXCR4). Scale bar = 50 μm. P-values are calculated using one-way ANOVA with Tukey's test, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, n.s. not significant ( b was created with bioRender. com).
Cxcr4 Blocking Antibody, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cxcr4/pmc12969473-305-22-28?v=MedChemExpress
Average 94 stars, based on 1 article reviews
cxcr4 blocking antibody - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

99
Thermo Fisher gene exp cxcr4 hs00607978 s1
nMSC@MT inheriting the original MSCs and could be effectively taken up by BMMSCs. a) Representative confocal images of PMVs with DiI-labeled cell membrane and Tht-labeled cytoplasm. Scale bar = 25 μm (above) and 1 μm (below). b) Illustration showing the co-extrusion procedure of nPMV and melatonin to obtain nMSC@MT. c) Representative TEM image of nMSC@MT. Scale bar = 100 nm. d, e) The sizes and the potential zetas of nPMV and nMSC@MT by DLS (n = 3). f, g) Coomassie brilliant blue and Western blot showing the preservation of stem cell markers, CD146, CD105, CD90, and functional protein, <t>CXCR4,</t> in PMV, nPMV, and nMSC@MT. h) DiI-labeled nMSC@MT (red) was detected in the cytoplasm of BMMSCs, suggesting the endocytosis of nMSC@MT. Scale bar = 10 μm. i) Immunofluorescence showing that a large amount of DiI-labeled nMSC@MT (red), released from the hydrogel, was taken up by CD146-labeled MSCs (green). Scale bar = 50 μm. j) BMMSCs uptake of DiI-labeled nMSC@MT in presence of blocking antibodies (anti-CXCR4) detected via flow cytometry. k) Analysis of the percentage of DiI positive cells in BMMSCs by flow cytometry (n = 3). l, m) Immunofluorescent staining images and corresponding semi-quantitative analysis (n = 3) of the uptake of DiI-labeled nPMV by BMMSCs in presence of blocking antibodies (anti-CXCR4). Scale bar = 50 μm. P-values are calculated using one-way ANOVA with Tukey's test, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, n.s. not significant ( b was created with bioRender. com).
Gene Exp Cxcr4 Hs00607978 S1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cxcr4/us12612620-4398-12--1?v=Thermo+Fisher
Average 99 stars, based on 1 article reviews
gene exp cxcr4 hs00607978 s1 - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier

95
MedChemExpress cxcr4 inhibitor intervention
High mobility group protein B1 (HMGB1) promotes interferon regulatory factor 1 (IRF1) SUMOylation via MyD88 to induce trained immunity in knee osteoarthritis (KOA) monocytes. (A) Western blotting (WB) was used to detect the expression levels of IRF1 and MyD88 proteins in peripheral blood monocytes from patients in the healthy donor (HD) and KOA groups ( n = 3). (B) WB was used to detect the expression levels of IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the negative control (NC) and HMGB1 groups ( n = 3). (C) Coimmunoprecipitation (CO-IP) was used to examine the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from patients in the HD and KOA groups. (D) CO-IP was used to examine the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the NC and HMGB1 groups. (E) A laser confocal microscope was used to observe the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the NC and HMGB1 groups. (F) CO-IP was used to evaluate the SUMOylation of IRF1 in peripheral blood monocytes from patients in the HD and KOA groups. (G) CO-IP was used to evaluate the SUMOylation of IRF1 in peripheral blood monocytes from mice in the NC and HMGB1 groups. (H) CO-IP was used to compare the differences in SUMOylation levels of IRF1 in peripheral blood monocytes from wild-type and MyD88 knockout mice after HMGB1 stimulation. (I) Enzyme-linked immunosorbent assay (ELISA) was used to measure the levels of interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) in peripheral blood monocytes from wild-type and MyD88 knockout mice after HMGB1 stimulation ( n = 6). (J) Flow cytometry was used to determine the proportion of <t>CXCR4-positive</t> cells in peripheral blood monocytes from wild-type mice stimulated with HMGB1 ( n = 3). (K) Flow cytometry was used to determine the proportion of CXCR4-positive cells in peripheral blood monocytes from MyD88 knockout mice stimulated with HMGB1 ( n = 3). Statistical results are represented by mean ± standard error of the mean (mean ± SEM), * P < 0.05, ** P < 0.01, *** P < 0.001.
Cxcr4 Inhibitor Intervention, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cxcr4/pmc13172585-276-2-11?v=MedChemExpress
Average 95 stars, based on 1 article reviews
cxcr4 inhibitor intervention - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier

93
Miltenyi Biotec cd184 cxcr4
High mobility group protein B1 (HMGB1) promotes interferon regulatory factor 1 (IRF1) SUMOylation via MyD88 to induce trained immunity in knee osteoarthritis (KOA) monocytes. (A) Western blotting (WB) was used to detect the expression levels of IRF1 and MyD88 proteins in peripheral blood monocytes from patients in the healthy donor (HD) and KOA groups ( n = 3). (B) WB was used to detect the expression levels of IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the negative control (NC) and HMGB1 groups ( n = 3). (C) Coimmunoprecipitation (CO-IP) was used to examine the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from patients in the HD and KOA groups. (D) CO-IP was used to examine the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the NC and HMGB1 groups. (E) A laser confocal microscope was used to observe the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the NC and HMGB1 groups. (F) CO-IP was used to evaluate the SUMOylation of IRF1 in peripheral blood monocytes from patients in the HD and KOA groups. (G) CO-IP was used to evaluate the SUMOylation of IRF1 in peripheral blood monocytes from mice in the NC and HMGB1 groups. (H) CO-IP was used to compare the differences in SUMOylation levels of IRF1 in peripheral blood monocytes from wild-type and MyD88 knockout mice after HMGB1 stimulation. (I) Enzyme-linked immunosorbent assay (ELISA) was used to measure the levels of interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) in peripheral blood monocytes from wild-type and MyD88 knockout mice after HMGB1 stimulation ( n = 6). (J) Flow cytometry was used to determine the proportion of <t>CXCR4-positive</t> cells in peripheral blood monocytes from wild-type mice stimulated with HMGB1 ( n = 3). (K) Flow cytometry was used to determine the proportion of CXCR4-positive cells in peripheral blood monocytes from MyD88 knockout mice stimulated with HMGB1 ( n = 3). Statistical results are represented by mean ± standard error of the mean (mean ± SEM), * P < 0.05, ** P < 0.01, *** P < 0.001.
Cd184 Cxcr4, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cxcr4/pm42034633-353-14-28?v=Miltenyi+Biotec
Average 93 stars, based on 1 article reviews
cd184 cxcr4 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

86
Nanoprobes Inc cxcr4
High mobility group protein B1 (HMGB1) promotes interferon regulatory factor 1 (IRF1) SUMOylation via MyD88 to induce trained immunity in knee osteoarthritis (KOA) monocytes. (A) Western blotting (WB) was used to detect the expression levels of IRF1 and MyD88 proteins in peripheral blood monocytes from patients in the healthy donor (HD) and KOA groups ( n = 3). (B) WB was used to detect the expression levels of IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the negative control (NC) and HMGB1 groups ( n = 3). (C) Coimmunoprecipitation (CO-IP) was used to examine the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from patients in the HD and KOA groups. (D) CO-IP was used to examine the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the NC and HMGB1 groups. (E) A laser confocal microscope was used to observe the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the NC and HMGB1 groups. (F) CO-IP was used to evaluate the SUMOylation of IRF1 in peripheral blood monocytes from patients in the HD and KOA groups. (G) CO-IP was used to evaluate the SUMOylation of IRF1 in peripheral blood monocytes from mice in the NC and HMGB1 groups. (H) CO-IP was used to compare the differences in SUMOylation levels of IRF1 in peripheral blood monocytes from wild-type and MyD88 knockout mice after HMGB1 stimulation. (I) Enzyme-linked immunosorbent assay (ELISA) was used to measure the levels of interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) in peripheral blood monocytes from wild-type and MyD88 knockout mice after HMGB1 stimulation ( n = 6). (J) Flow cytometry was used to determine the proportion of <t>CXCR4-positive</t> cells in peripheral blood monocytes from wild-type mice stimulated with HMGB1 ( n = 3). (K) Flow cytometry was used to determine the proportion of CXCR4-positive cells in peripheral blood monocytes from MyD88 knockout mice stimulated with HMGB1 ( n = 3). Statistical results are represented by mean ± standard error of the mean (mean ± SEM), * P < 0.05, ** P < 0.01, *** P < 0.001.
Cxcr4, supplied by Nanoprobes Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cxcr4/pm42032783-307-21-24?v=Nanoprobes+Inc
Average 86 stars, based on 1 article reviews
cxcr4 - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

96
Bio-Techne corporation mouse cxcr4 antibody
High mobility group protein B1 (HMGB1) promotes interferon regulatory factor 1 (IRF1) SUMOylation via MyD88 to induce trained immunity in knee osteoarthritis (KOA) monocytes. (A) Western blotting (WB) was used to detect the expression levels of IRF1 and MyD88 proteins in peripheral blood monocytes from patients in the healthy donor (HD) and KOA groups ( n = 3). (B) WB was used to detect the expression levels of IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the negative control (NC) and HMGB1 groups ( n = 3). (C) Coimmunoprecipitation (CO-IP) was used to examine the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from patients in the HD and KOA groups. (D) CO-IP was used to examine the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the NC and HMGB1 groups. (E) A laser confocal microscope was used to observe the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the NC and HMGB1 groups. (F) CO-IP was used to evaluate the SUMOylation of IRF1 in peripheral blood monocytes from patients in the HD and KOA groups. (G) CO-IP was used to evaluate the SUMOylation of IRF1 in peripheral blood monocytes from mice in the NC and HMGB1 groups. (H) CO-IP was used to compare the differences in SUMOylation levels of IRF1 in peripheral blood monocytes from wild-type and MyD88 knockout mice after HMGB1 stimulation. (I) Enzyme-linked immunosorbent assay (ELISA) was used to measure the levels of interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) in peripheral blood monocytes from wild-type and MyD88 knockout mice after HMGB1 stimulation ( n = 6). (J) Flow cytometry was used to determine the proportion of <t>CXCR4-positive</t> cells in peripheral blood monocytes from wild-type mice stimulated with HMGB1 ( n = 3). (K) Flow cytometry was used to determine the proportion of CXCR4-positive cells in peripheral blood monocytes from MyD88 knockout mice stimulated with HMGB1 ( n = 3). Statistical results are represented by mean ± standard error of the mean (mean ± SEM), * P < 0.05, ** P < 0.01, *** P < 0.001.
Mouse Cxcr4 Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cxcr4/bio-techne+corporation___mab21651?v=Bio-Techne+corporation
Average 96 stars, based on 1 article reviews
mouse cxcr4 antibody - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier

94
MedChemExpress cxcr4 inhibitor amd3100
High mobility group protein B1 (HMGB1) promotes interferon regulatory factor 1 (IRF1) SUMOylation via MyD88 to induce trained immunity in knee osteoarthritis (KOA) monocytes. (A) Western blotting (WB) was used to detect the expression levels of IRF1 and MyD88 proteins in peripheral blood monocytes from patients in the healthy donor (HD) and KOA groups ( n = 3). (B) WB was used to detect the expression levels of IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the negative control (NC) and HMGB1 groups ( n = 3). (C) Coimmunoprecipitation (CO-IP) was used to examine the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from patients in the HD and KOA groups. (D) CO-IP was used to examine the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the NC and HMGB1 groups. (E) A laser confocal microscope was used to observe the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the NC and HMGB1 groups. (F) CO-IP was used to evaluate the SUMOylation of IRF1 in peripheral blood monocytes from patients in the HD and KOA groups. (G) CO-IP was used to evaluate the SUMOylation of IRF1 in peripheral blood monocytes from mice in the NC and HMGB1 groups. (H) CO-IP was used to compare the differences in SUMOylation levels of IRF1 in peripheral blood monocytes from wild-type and MyD88 knockout mice after HMGB1 stimulation. (I) Enzyme-linked immunosorbent assay (ELISA) was used to measure the levels of interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) in peripheral blood monocytes from wild-type and MyD88 knockout mice after HMGB1 stimulation ( n = 6). (J) Flow cytometry was used to determine the proportion of <t>CXCR4-positive</t> cells in peripheral blood monocytes from wild-type mice stimulated with HMGB1 ( n = 3). (K) Flow cytometry was used to determine the proportion of CXCR4-positive cells in peripheral blood monocytes from MyD88 knockout mice stimulated with HMGB1 ( n = 3). Statistical results are represented by mean ± standard error of the mean (mean ± SEM), * P < 0.05, ** P < 0.01, *** P < 0.001.
Cxcr4 Inhibitor Amd3100, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cxcr4/pm41950806-60-23-27?v=MedChemExpress
Average 94 stars, based on 1 article reviews
cxcr4 inhibitor amd3100 - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

93
Boster Bio anti cxcr4
High mobility group protein B1 (HMGB1) promotes interferon regulatory factor 1 (IRF1) SUMOylation via MyD88 to induce trained immunity in knee osteoarthritis (KOA) monocytes. (A) Western blotting (WB) was used to detect the expression levels of IRF1 and MyD88 proteins in peripheral blood monocytes from patients in the healthy donor (HD) and KOA groups ( n = 3). (B) WB was used to detect the expression levels of IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the negative control (NC) and HMGB1 groups ( n = 3). (C) Coimmunoprecipitation (CO-IP) was used to examine the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from patients in the HD and KOA groups. (D) CO-IP was used to examine the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the NC and HMGB1 groups. (E) A laser confocal microscope was used to observe the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the NC and HMGB1 groups. (F) CO-IP was used to evaluate the SUMOylation of IRF1 in peripheral blood monocytes from patients in the HD and KOA groups. (G) CO-IP was used to evaluate the SUMOylation of IRF1 in peripheral blood monocytes from mice in the NC and HMGB1 groups. (H) CO-IP was used to compare the differences in SUMOylation levels of IRF1 in peripheral blood monocytes from wild-type and MyD88 knockout mice after HMGB1 stimulation. (I) Enzyme-linked immunosorbent assay (ELISA) was used to measure the levels of interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) in peripheral blood monocytes from wild-type and MyD88 knockout mice after HMGB1 stimulation ( n = 6). (J) Flow cytometry was used to determine the proportion of <t>CXCR4-positive</t> cells in peripheral blood monocytes from wild-type mice stimulated with HMGB1 ( n = 3). (K) Flow cytometry was used to determine the proportion of CXCR4-positive cells in peripheral blood monocytes from MyD88 knockout mice stimulated with HMGB1 ( n = 3). Statistical results are represented by mean ± standard error of the mean (mean ± SEM), * P < 0.05, ** P < 0.01, *** P < 0.001.
Anti Cxcr4, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cxcr4/pm41925939-150-13-15?v=Boster+Bio
Average 93 stars, based on 1 article reviews
anti cxcr4 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

Image Search Results


nMSC@MT inheriting the original MSCs and could be effectively taken up by BMMSCs. a) Representative confocal images of PMVs with DiI-labeled cell membrane and Tht-labeled cytoplasm. Scale bar = 25 μm (above) and 1 μm (below). b) Illustration showing the co-extrusion procedure of nPMV and melatonin to obtain nMSC@MT. c) Representative TEM image of nMSC@MT. Scale bar = 100 nm. d, e) The sizes and the potential zetas of nPMV and nMSC@MT by DLS (n = 3). f, g) Coomassie brilliant blue and Western blot showing the preservation of stem cell markers, CD146, CD105, CD90, and functional protein, CXCR4, in PMV, nPMV, and nMSC@MT. h) DiI-labeled nMSC@MT (red) was detected in the cytoplasm of BMMSCs, suggesting the endocytosis of nMSC@MT. Scale bar = 10 μm. i) Immunofluorescence showing that a large amount of DiI-labeled nMSC@MT (red), released from the hydrogel, was taken up by CD146-labeled MSCs (green). Scale bar = 50 μm. j) BMMSCs uptake of DiI-labeled nMSC@MT in presence of blocking antibodies (anti-CXCR4) detected via flow cytometry. k) Analysis of the percentage of DiI positive cells in BMMSCs by flow cytometry (n = 3). l, m) Immunofluorescent staining images and corresponding semi-quantitative analysis (n = 3) of the uptake of DiI-labeled nPMV by BMMSCs in presence of blocking antibodies (anti-CXCR4). Scale bar = 50 μm. P-values are calculated using one-way ANOVA with Tukey's test, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, n.s. not significant ( b was created with bioRender. com).

Journal: Bioactive Materials

Article Title: MSC-mimicking nanovesicle embedded bio-adhesive hydrogel for dual immunomodulation and osteogenesis to promote maxillofacial bone regeneration

doi: 10.1016/j.bioactmat.2026.02.032

Figure Lengend Snippet: nMSC@MT inheriting the original MSCs and could be effectively taken up by BMMSCs. a) Representative confocal images of PMVs with DiI-labeled cell membrane and Tht-labeled cytoplasm. Scale bar = 25 μm (above) and 1 μm (below). b) Illustration showing the co-extrusion procedure of nPMV and melatonin to obtain nMSC@MT. c) Representative TEM image of nMSC@MT. Scale bar = 100 nm. d, e) The sizes and the potential zetas of nPMV and nMSC@MT by DLS (n = 3). f, g) Coomassie brilliant blue and Western blot showing the preservation of stem cell markers, CD146, CD105, CD90, and functional protein, CXCR4, in PMV, nPMV, and nMSC@MT. h) DiI-labeled nMSC@MT (red) was detected in the cytoplasm of BMMSCs, suggesting the endocytosis of nMSC@MT. Scale bar = 10 μm. i) Immunofluorescence showing that a large amount of DiI-labeled nMSC@MT (red), released from the hydrogel, was taken up by CD146-labeled MSCs (green). Scale bar = 50 μm. j) BMMSCs uptake of DiI-labeled nMSC@MT in presence of blocking antibodies (anti-CXCR4) detected via flow cytometry. k) Analysis of the percentage of DiI positive cells in BMMSCs by flow cytometry (n = 3). l, m) Immunofluorescent staining images and corresponding semi-quantitative analysis (n = 3) of the uptake of DiI-labeled nPMV by BMMSCs in presence of blocking antibodies (anti-CXCR4). Scale bar = 50 μm. P-values are calculated using one-way ANOVA with Tukey's test, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, n.s. not significant ( b was created with bioRender. com).

Article Snippet: To evaluate the involvement of CXCR4 in the uptake of nPMV, prior to co-culture with BMMSCs, nPMV was pre-treated with 160 nM CXCR4 blocking antibody (Ulocuplumab, Cat. HY-P99272, MedChemExpress, China) at room temperature for 1 h. Then nPMV was introduced into BMMSC cultures and incubated for 24 h. Subsequent analyses included flow cytometric analysis and immunofluorescence staining. nPMV without blocking antibody was served as a control.

Techniques: Labeling, Membrane, Western Blot, Preserving, Functional Assay, Immunofluorescence, Blocking Assay, Flow Cytometry, Staining

High mobility group protein B1 (HMGB1) promotes interferon regulatory factor 1 (IRF1) SUMOylation via MyD88 to induce trained immunity in knee osteoarthritis (KOA) monocytes. (A) Western blotting (WB) was used to detect the expression levels of IRF1 and MyD88 proteins in peripheral blood monocytes from patients in the healthy donor (HD) and KOA groups ( n = 3). (B) WB was used to detect the expression levels of IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the negative control (NC) and HMGB1 groups ( n = 3). (C) Coimmunoprecipitation (CO-IP) was used to examine the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from patients in the HD and KOA groups. (D) CO-IP was used to examine the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the NC and HMGB1 groups. (E) A laser confocal microscope was used to observe the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the NC and HMGB1 groups. (F) CO-IP was used to evaluate the SUMOylation of IRF1 in peripheral blood monocytes from patients in the HD and KOA groups. (G) CO-IP was used to evaluate the SUMOylation of IRF1 in peripheral blood monocytes from mice in the NC and HMGB1 groups. (H) CO-IP was used to compare the differences in SUMOylation levels of IRF1 in peripheral blood monocytes from wild-type and MyD88 knockout mice after HMGB1 stimulation. (I) Enzyme-linked immunosorbent assay (ELISA) was used to measure the levels of interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) in peripheral blood monocytes from wild-type and MyD88 knockout mice after HMGB1 stimulation ( n = 6). (J) Flow cytometry was used to determine the proportion of CXCR4-positive cells in peripheral blood monocytes from wild-type mice stimulated with HMGB1 ( n = 3). (K) Flow cytometry was used to determine the proportion of CXCR4-positive cells in peripheral blood monocytes from MyD88 knockout mice stimulated with HMGB1 ( n = 3). Statistical results are represented by mean ± standard error of the mean (mean ± SEM), * P < 0.05, ** P < 0.01, *** P < 0.001.

Journal: Research

Article Title: High Mobility Group Protein B1 Promotes Interferon Regulatory Factor 1 SUMOylation to Prime Trained Immunity of Circulating Monocytes and Aggravate the Progressive Synovial Inflammation in Knee Osteoarthritis

doi: 10.34133/research.1243

Figure Lengend Snippet: High mobility group protein B1 (HMGB1) promotes interferon regulatory factor 1 (IRF1) SUMOylation via MyD88 to induce trained immunity in knee osteoarthritis (KOA) monocytes. (A) Western blotting (WB) was used to detect the expression levels of IRF1 and MyD88 proteins in peripheral blood monocytes from patients in the healthy donor (HD) and KOA groups ( n = 3). (B) WB was used to detect the expression levels of IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the negative control (NC) and HMGB1 groups ( n = 3). (C) Coimmunoprecipitation (CO-IP) was used to examine the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from patients in the HD and KOA groups. (D) CO-IP was used to examine the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the NC and HMGB1 groups. (E) A laser confocal microscope was used to observe the interaction between IRF1 and MyD88 proteins in peripheral blood monocytes from mice in the NC and HMGB1 groups. (F) CO-IP was used to evaluate the SUMOylation of IRF1 in peripheral blood monocytes from patients in the HD and KOA groups. (G) CO-IP was used to evaluate the SUMOylation of IRF1 in peripheral blood monocytes from mice in the NC and HMGB1 groups. (H) CO-IP was used to compare the differences in SUMOylation levels of IRF1 in peripheral blood monocytes from wild-type and MyD88 knockout mice after HMGB1 stimulation. (I) Enzyme-linked immunosorbent assay (ELISA) was used to measure the levels of interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) in peripheral blood monocytes from wild-type and MyD88 knockout mice after HMGB1 stimulation ( n = 6). (J) Flow cytometry was used to determine the proportion of CXCR4-positive cells in peripheral blood monocytes from wild-type mice stimulated with HMGB1 ( n = 3). (K) Flow cytometry was used to determine the proportion of CXCR4-positive cells in peripheral blood monocytes from MyD88 knockout mice stimulated with HMGB1 ( n = 3). Statistical results are represented by mean ± standard error of the mean (mean ± SEM), * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: For the CXCR4 inhibitor intervention, mice were injected with plerixafor (HY-10046, MCE, USA) at a dose of 5 mg/kg into the tail vein.

Techniques: Western Blot, Expressing, Negative Control, Co-Immunoprecipitation Assay, Microscopy, Knock-Out, Enzyme-linked Immunosorbent Assay, Flow Cytometry

Inhibition of high mobility group protein B1 (HMGB1) eliminated the trained immunity of circulating monocytes and their aggregation to knee osteoarthritis (KOA) synovial tissue. (A) In vivo imaging was used to observe the locations of cell migration in the KOA group, the KOA group with transfused fluorescently labeled trained circulating monocytes, and the KOA group with transfused fluorescently labeled untrained circulating monocytes in mice ( n = 3). (B) Enzyme-linked immunosorbent assay (ELISA) was performed to measure the levels of interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) in mouse peripheral serum at different time points under Nab-HMGB1 intervention ( n = 6). (C) Western blotting (WB) was used to detect the expression of IL-1β, IL-6, and TNF-α in mouse synovial tissue at different time points following Nab-HMGB1 intervention. (D) Representative WB bands showing the levels of IL-1β, IL-6, and TNF-α in peripheral circulating monocytes from mice at different time points under Nab-HMGB1 intervention ( n = 3). (E) Statistical graphs of the WB results for IL-1β, IL-6, and TNF-α levels in peripheral circulating monocytes from mice at different time points under Nab-HMGB1 intervention. (F) Representative WB bands showing the levels of IL-1β, IL-6, and TNF-α in peripheral circulating monocytes from mice at different time points under Nab-HMGB1 intervention ( n = 3). (G) Immunofluorescence was used to observe the numbers of CXCR4 + and Ly6c + cells in synovial tissue from the negative control (NC) group, KOA group, and Nab-HMGB1 group of mice. (H) The number of CXCR4 + circulating monocytes in mouse synovial tissue from the NC group, KOA group, and Nab-HMGB1 group was detected using magnetic bead sorting of mouse circulating monocytes followed by flow cytometry ( n = 3). Statistical results are represented by mean ± standard error of the mean (mean ± SEM), * P < 0.05, ** P < 0.01, *** P < 0.001. NS, not significant.

Journal: Research

Article Title: High Mobility Group Protein B1 Promotes Interferon Regulatory Factor 1 SUMOylation to Prime Trained Immunity of Circulating Monocytes and Aggravate the Progressive Synovial Inflammation in Knee Osteoarthritis

doi: 10.34133/research.1243

Figure Lengend Snippet: Inhibition of high mobility group protein B1 (HMGB1) eliminated the trained immunity of circulating monocytes and their aggregation to knee osteoarthritis (KOA) synovial tissue. (A) In vivo imaging was used to observe the locations of cell migration in the KOA group, the KOA group with transfused fluorescently labeled trained circulating monocytes, and the KOA group with transfused fluorescently labeled untrained circulating monocytes in mice ( n = 3). (B) Enzyme-linked immunosorbent assay (ELISA) was performed to measure the levels of interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) in mouse peripheral serum at different time points under Nab-HMGB1 intervention ( n = 6). (C) Western blotting (WB) was used to detect the expression of IL-1β, IL-6, and TNF-α in mouse synovial tissue at different time points following Nab-HMGB1 intervention. (D) Representative WB bands showing the levels of IL-1β, IL-6, and TNF-α in peripheral circulating monocytes from mice at different time points under Nab-HMGB1 intervention ( n = 3). (E) Statistical graphs of the WB results for IL-1β, IL-6, and TNF-α levels in peripheral circulating monocytes from mice at different time points under Nab-HMGB1 intervention. (F) Representative WB bands showing the levels of IL-1β, IL-6, and TNF-α in peripheral circulating monocytes from mice at different time points under Nab-HMGB1 intervention ( n = 3). (G) Immunofluorescence was used to observe the numbers of CXCR4 + and Ly6c + cells in synovial tissue from the negative control (NC) group, KOA group, and Nab-HMGB1 group of mice. (H) The number of CXCR4 + circulating monocytes in mouse synovial tissue from the NC group, KOA group, and Nab-HMGB1 group was detected using magnetic bead sorting of mouse circulating monocytes followed by flow cytometry ( n = 3). Statistical results are represented by mean ± standard error of the mean (mean ± SEM), * P < 0.05, ** P < 0.01, *** P < 0.001. NS, not significant.

Article Snippet: For the CXCR4 inhibitor intervention, mice were injected with plerixafor (HY-10046, MCE, USA) at a dose of 5 mg/kg into the tail vein.

Techniques: Inhibition, In Vivo Imaging, Migration, Labeling, Enzyme-linked Immunosorbent Assay, Western Blot, Expressing, Immunofluorescence, Negative Control, Flow Cytometry

CXCR4-dependent migration of trained subsets promoted synovial inflammation in knee osteoarthritis (KOA). (A) Flow cytometry was used to assess the effects of high mobility group protein B1 (HMGB1), CCL4, and interleukin-18 (IL-18) treatments on the proportion of CXCR4-positive cells among circulating monocytes in mice ( n = 3). (B) CXCR4 + cells were isolated using flow cytometric sorting. (C) Principal component analysis (PCA) was performed on CXCR4 + and CXCR4 − cells. (D) A volcano plot displays the number of differentially expressed genes between CXCR4 + and CXCR4 − cells. (E) Kyoto Encyclopedia of Genes and Genomes (KEGG) database enrichment analysis was conducted for the differentially expressed genes between CXCR4 + and CXCR4 − cells. (F) In vivo animal fluorescence imaging demonstrates the effects of transfusing CXCR4 + cells and administering the CXCR4 receptor antagonist plerixafor on CXCR4 + cells in KOA mice ( n = 3). (G) Hematoxylin and eosin (HE) staining was used to observe synovial pathology in the KOA group, the CXCR4 + cell transfusion group, and the CXCR4 + cell transfusion plus plerixafor group. (H) Representative Western blot images show protein expression levels of IL-1β, IL-6, and tumor necrosis factor-α (TNF-α) in the synovial tissue of mice from the KOA group, CXCR4 + cell transfusion group, and CXCR4 + cell transfusion plus plerixafor group. (I) Quantitative Western blot analysis of IL-1β, IL-6, and TNF-α protein expression levels in synovial tissue from the 3 groups ( n = 3). (J) Quantitative polymerase chain reaction (PCR) analysis of IL-1β, IL-6, and TNF-α mRNA expression levels in synovial tissue from the KOA group, CXCR4 + cell transfusion group, and CXCR4 + cell transfusion plus plerixafor group ( n = 3). Statistical results are represented by mean ± standard error of the mean (mean ± SEM), ** P < 0.01, *** P < 0.001.

Journal: Research

Article Title: High Mobility Group Protein B1 Promotes Interferon Regulatory Factor 1 SUMOylation to Prime Trained Immunity of Circulating Monocytes and Aggravate the Progressive Synovial Inflammation in Knee Osteoarthritis

doi: 10.34133/research.1243

Figure Lengend Snippet: CXCR4-dependent migration of trained subsets promoted synovial inflammation in knee osteoarthritis (KOA). (A) Flow cytometry was used to assess the effects of high mobility group protein B1 (HMGB1), CCL4, and interleukin-18 (IL-18) treatments on the proportion of CXCR4-positive cells among circulating monocytes in mice ( n = 3). (B) CXCR4 + cells were isolated using flow cytometric sorting. (C) Principal component analysis (PCA) was performed on CXCR4 + and CXCR4 − cells. (D) A volcano plot displays the number of differentially expressed genes between CXCR4 + and CXCR4 − cells. (E) Kyoto Encyclopedia of Genes and Genomes (KEGG) database enrichment analysis was conducted for the differentially expressed genes between CXCR4 + and CXCR4 − cells. (F) In vivo animal fluorescence imaging demonstrates the effects of transfusing CXCR4 + cells and administering the CXCR4 receptor antagonist plerixafor on CXCR4 + cells in KOA mice ( n = 3). (G) Hematoxylin and eosin (HE) staining was used to observe synovial pathology in the KOA group, the CXCR4 + cell transfusion group, and the CXCR4 + cell transfusion plus plerixafor group. (H) Representative Western blot images show protein expression levels of IL-1β, IL-6, and tumor necrosis factor-α (TNF-α) in the synovial tissue of mice from the KOA group, CXCR4 + cell transfusion group, and CXCR4 + cell transfusion plus plerixafor group. (I) Quantitative Western blot analysis of IL-1β, IL-6, and TNF-α protein expression levels in synovial tissue from the 3 groups ( n = 3). (J) Quantitative polymerase chain reaction (PCR) analysis of IL-1β, IL-6, and TNF-α mRNA expression levels in synovial tissue from the KOA group, CXCR4 + cell transfusion group, and CXCR4 + cell transfusion plus plerixafor group ( n = 3). Statistical results are represented by mean ± standard error of the mean (mean ± SEM), ** P < 0.01, *** P < 0.001.

Article Snippet: For the CXCR4 inhibitor intervention, mice were injected with plerixafor (HY-10046, MCE, USA) at a dose of 5 mg/kg into the tail vein.

Techniques: Migration, Flow Cytometry, Isolation, In Vivo, Fluorescence, Imaging, Staining, Western Blot, Expressing, Real-time Polymerase Chain Reaction